Nonstatin Drugs (WB Borden, Section Editor)

Current Atherosclerosis Reports

, 16:382

First online:

Novel Therapies for Treating Familial Hypercholesterolemia

  • Salman J. BandealiAffiliated withSection of Cardiology, Department of Medicine, Texas Heart Institute, St. Luke’s Episcopal Hospital
  • , Jad DayeAffiliated withDepartment of Medicine, Baylor College of Medicine
  • , Salim S. ViraniAffiliated withDepartment of Medicine, Baylor College of MedicineHealth Policy, Quality, and Informatics Program, Michael E. DeBakey Veteran Affairs Medical Center Health Services Research and Development Center of ExcellenceSection of Cardiovascular Research, Department of Medicine, Baylor College of MedicineCenter for Cardiovascular Disease Prevention, Houston Methodist DeBakey Heart and Vascular CenterSection of Cardiology, Michael E. DeBakey Veterans Affairs Medical CenterHealth Services Research and Development (152), Michael E. DeBakey Veterans Affairs Medical Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Familial hypercholesterolemia is an inherited disorder associated with early accelerated atherosclerosis with morbidity and mortality resulting from premature cardiovascular disease. Affected individuals have extreme elevations in low-density lipoprotein cholesterol levels. Patients usually do not achieve target reductions in cholesterol levels with conventional antihyperlipidemic pharmacotherapy. This unmet need has resulted in the recent development and approval of novel therapies targeting different cholesterol pathways. This article briefly summarizes familial hypercholesterolemia and then discusses the newer pharmacotherapies available in the management of familial hypercholesterolemia.


Familial hypercholesterolemia Mipomersen Proprotein convertase subtilisin/kexin 9 inhibitors Lomitapide